APA 6th referencing styleAssignment has two section01.Case Study Report - 60% - Word Count...

Question

APA 6th referencing styleAssignment has two section01.Case Study Report - 60% - Word Count 3,00002.Project Schedule and Cost Management Plans - 40% - Word Count 1,500			Total Word Count 5,000.Time - 24 hoursPROBIOTEC ANNUAL REPORT 20222 Contents Chairman’s Letter to Shareholders    CEO Update  Key Highlights    Results Summary   Strategy    Corporate Governance Statement    Financial Report    Other Information Required by ASX 3 5 8 9 12 13 18 80 Registered office  83 Cherry Lane,  Laverton North,  Victoria 3026  Ph: (03) 9278 7555  Probiotec Limited  ABN 91 075 170 151  Probiotec Limited  and its controlled entities  ACN 075 170 151    Annual Report  for the year ended  30 June 2022 PROBIOTEC ANNUAL REPORT 20223 Chairman’s Letter to  Shareholders Dear Shareholders, On behalf of your board of directors, it gives me great pleasure to present to you the 2022 Annual Report for Probiotec  Limited (PBP). We are proud of what the group has achieved against a difficult operating backdrop. The performance over the past 12  months is testament to the defensible and resilient business model of Probiotec and to the commitment of the wider  Probiotec team. The last 12 months have certainly tested us and thrown a number of challenges our way. In the face of unprecedented supply chain disruption, labour shortages, inflation and a myriad of operating challenges the  company has continued to grow and deliver for shareholders. Tailwinds merging I believe as a result of the pandemic there has and will continue to be a fundamental shift in global supply chains. As such,  the outlook for domestic manufacturing, especially in specialist industries such as the pharmaceutical industry in which  Probiotec primarily operates, is materially improved. The pandemic has brought to the forefront the need for Australia to have increased sovereign manufacturing capability.  Along with this, brand owners need to bring their supply chains closer to or within region to provide greater responsiveness  and flexibility to the market and world events. We have seen widespread supply chain disruption and significant freight cost increases along with political and global  instability. All of these events have fundamentally shifted the pendulum in favour of local manufacturing and supply or at  least a diversification of supply chains resulting in more domestic supply. This onshoring of manufacturing has certainly commenced and we see this as an industry tailwind that is likely to benefit  Probiotec for the foreseeable future. Strong financial and operational performance Record revenues of $182 million were accompanied by Earnings Before Interest, Tax, Depreciation and Amortisation  (EBITDA) of $32.8 million. These results demonstrate the robust and defensive nature of the PBP business. The results  are a testament to the leadership of the PBP management team and the dedication and skills of our employees.  Management remained agile in the operation of all PBP sites to ensure they remained safe and efficient as conditions  evolved. The health and safety of PBP’s employees remains at the forefront of our thinking.  Through the ongoing refinement of work practices, the flexibility of our work force, customer and supplier co-operation  and nimbleness in execution we believe we are emerging from the pandemic in a stronger position than we entered.  The pressures on management and the wider Probiotec team have remained at elevated levels and I wish to convey my  PROBIOTEC ANNUAL REPORT 20224 sincerest thanks to the entire team who showed tremendous commitment over the past year. Their professionalism has  prioritised safety, whilst we have seen delivery performance to our customers remain at the highest levels. Outlook for the future Whilst a level of uncertainty persists, the board and management expect to deliver growth in both sales and earnings  again in FY23.  In the short term, we see: • The continuation of the recovery and full year effect of cough, cold and flu category sales. We also believe that the  category will sit above historical levels for the near future, given the ongoing nature of Covid-19 and the level of virus  and transmission in the community; • New business wins which have been delayed during the pandemic have started to flow and will continue to flow into  FY23 and FY24; and • Supply chain impacts, freight costs, and labour shortages continuing to provide operational and cost challenges albeit  with management continuing to navigate these well. Looking to FY24 and beyond: • We are confident that onshoring industry tailwinds will continue to gather momentum and result in increasing  opportunities for the group (across the breadth of our business); • We see significant breadth and depth of opportunity given the blue-chip nature of our client base; • We continue to win new business and build the future pipeline, and we expect further realisation and delivery of prior  new business wins; • Realisation of synergies from site consolidation and further cost-out and rationalisation as the group comes together  and the acquisitions completed over the past 2 to 3 years are fully integrated. Over the longer term, it continues to be our objective to become Australia’s leading manufacturer and packer of  pharmaceutical, consumer health and FMCG products. We will continue to pursue value-accretive acquisitions; to invest  in customer and site capabilities; to invest in and develop our people; to expand our relationships with Tier 1 customers;  and to maximise opportunities that arise from the onshoring of domestic manufacturing. The achievement of this goal  will require the continued support of all our stakeholders - customers, suppliers, employees and shareholders - and we  are grateful for the opportunity to work with all of you and for your support. Conclusion As I enter my second year as Chairman, I am more excited than ever about the prospects of the company and look forward  to contributing to the continuation of the growth journey we remain committed to.   I wish to thank my fellow directors for their guidance, counsel and steady hands over the past year and look forward to  continuing to take the company forward together. The results achieved would not have been possible without the leadership, vision and dedication of our CEO Wes Stringer,  along with his entire executive team and all the staff at Probiotec. The entire team’s focus on excellence has again been  demonstrated in this year’s result and the positioning of the company for the future. Yours sincerely, Jonathan Wenig Chairman of the board PROBIOTEC ANNUAL REPORT 20225 CEO Update Dear Shareholders, In what has been another challenging but very successful  year I am immensely proud of the entire Probiotec team  for their dedication and commitment to excellence. Record  revenue and earnings were achieved again against the  backdrop of the ongoing covid-19 pandemic, geopolitical  issues, supply chain disruptions and inflationary cost  pressures.  Key Achievements 	Record revenue: $182.3m 	Record EBITDA: Underlying¹ $32.8m 	Net Debt / EBITDA

Sandeep · Accepted Answer

Profitability Ratios
	Profitability and Market Ratios - COMPANY ASX CODE
			2021	2022	Average for Industry	Industry average to be provided by facilitator
	Return on Equity	Net Profit / Average Equity	Net Profit Year 1 / ((OE Year 1 + OE Year 2)/2)	Net Profit Year 2 /  (( OE Year 2 + OE Year 3)/2)
			0	0
			7.51%	18.56%
	Return on Assets	Net Profit / Average Total Assets	Net Profit Year 1 / ((Total A Year 1 + Total A Year 2)/2)	Net Profit Year 2 / ((Total A Year 2 + Total A Year 3)/2)
			0	0
			2.66%	5.84%	result %
	Gross Profit Margin	Gross Profit / Sales or Revenue	Gross Profit Year 1 / Sales or Revenue Year 1	Gross Profit Year 2 / Sales or Revenue Year 2
			0	0
			32.23%	31.32%	result %
	Net Profit Margin	Net Profit / Sales or Revenue	Net Profit Year 1  / Sales or Revenue Year 1	Net Profit Year 2  / Sales or Revenue Year 2
			0	0
			4.01%	7.53%	result %
	Net Interest Income	Net Interest Income / Average Interest Earning Assets or Total Assets	(Interest Income Year 1 - Interest Expense Year 1) / ((Total A Year 1 + Total A Year 2)/2)	(Interest Income Year 2 - Interest Expense Year 2) / ((Total A Year 2 + Total A Year 3)/2)
		for Banks only, these values are reported in the annual report 	0	0
			1.86%	1.83%	result %
	Expense ratio	Expenses (excluding tax) / Sales or Revenue	Expenses Year 1 / Sales or Revenue Year 1	Expenses Year 2 / Sales or Revenue Year 2
			0	0
			16.12%	14.84%	result %
	Cash flow to sales	Net Cash from Operating Activities / Sales or Revenue	Cashflows from Operating Activities Year 1 / Sales or Revenue Year 1	Cashflows from Operating Activities Year 2 / Sales or Revenue Year 2
			0	0
			20.66%	10.

APA 6th referencing styleAssignment has two section01.Case Study Report - 60% - Word Count 3,00002.Project Schedule and Cost Management Plans - 40% - Word Count 1,500Total Word Count 5,000.Time - 24...

Answer To: APA 6th referencing styleAssignment has two section01.Case Study Report - 60% - Word Count...

Answer To This Question Is Available To Download

Related Questions & Answers